Clinical Trial

MDR - PMCF Study for Taperloc Complete Stems

Recruiting
View on ClinicalTrials.gov →
Summary
The objective of this consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the Taperloc Complete stems when used for primary or revision total hip arthroplasty (implants) at 1,3,5,7 and 10-year follow-up\*. Since Taperloc Complete was introduced to the EU in 2010, all available retrospective data will be collected from each patient and a prospective aspect to the study will be necessary to reach the 10-year time point.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2019-07-18; most recent amendment 2025-03-10.
Status change: Not Yet Recruiting → Recruiting 2020-03-26
Trial Details
NCT Number NCT04028687
Lead Sponsor Zimmer Biomet
Conditions Hip Arthritis, Hip Disease, Hip Fractures, Hip Injuries, Hip Pain Chronic
Enrollment 820 participants
Start Date 2020-02-13
Primary Completion 2032-02-12 (estimated)
Study Completion 2032-02-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-11